Metavesco Inc (MVCO): Totally bizarre..........

Play Episode

4min

Proactive - Interviews for investors

Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management

Tonix Pharmaceuticals is making waves in the healthcare industry with the launch of TONIX ONE™ a fully integrated digital platform designed to empower migraine patients with better tools for understanding and managing their condition. In an exclusive discussion with Proactive’s Steve Darling, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, unveiled the platform’s innovative features and strategic partnerships aimed at transforming migraine care. By collaborating with UpScript Telemedicine, ProModRx, Blink Health, and a leading mobile application specializing in disease tracking, symptom reporting, and management, TONIX ONE offers a comprehensive, patient-centric solution. Dr. Lederman highlighted that TONIX ONE™ beyond conventional migraine education by providing critical insights into the limitations of oral medications, which can sometimes result in delayed or ineffective symptom relief. The platform bridges the gap between patients and healthcare providers, offering direct access to migraine specialists via telehealth consultations and seamless e-prescription requests—ensuring a faster, more effective pathway to treatment. With this initiative, Tonix Pharmaceuticals aims to not only educate and empower patients in their treatment journey but also eliminate the barriers to care that many migraine sufferers face. By integrating advanced digital health solutions,TONIX ONE™ stands at the forefront of a new era in migraine management, offering patients greater control over their health and well-being. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MigraineTreatment #TonixOne #DigitalHealth #Telemedicine #ZembraceSymTouch #Tosymra #HealthcareInnovation #PharmaNews #ProactiveInvestors

Proactive - Interviews for investors

Greatland Gold CEO on strong Q1, 'remarkable' Telfer integration and ASX listing plans

Greatland Gold PLC (AIM:GGP, OTC:GRLGF) CEO Shaun Day talked with Proactive about the company’s performance during the March quarter and its strategic progress with the Telfer asset. Day said the company generated A$253.00 million in free cash flow, lifting the total bank balance to A$398.00 million and maintaining a debt-free position. “I think that’s just a remarkable outcome after four months of ownership,” Day stated. Production for the quarter exceeded 90,000oz of gold equivalent, surpassing internal and market expectations. Costs also came in lower than forecast, with an all-in sustaining cost around A$2,100 per ounce. The company is investing heavily in revitalising Telfer, tripling the number of drill rigs to six and initiating the Stage 7 cutback at West Dome. Underground, high-grade intercepts at West Dome and a newly commissioned second decline highlight Greatland’s focus on long-term growth. Day also discussed the company's guidance for the seven months to June 2025, forecasting between 196,000oz and 210,000oz at an all-in sustaining cost of A$2,100–A$2,250 per ounce. He emphasised the margin potential at current gold prices exceeding A$5,000 per ounce. In addition, the company has formally commenced its ASX listing process, with dual listings in London and Australia expected by late June. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #GreatlandGold #ShaunDay #GoldMining #TelferMine #ASXListing #GoldProduction #Copper #AIMMarket #AustralianMining #ResourceStocks #MiningUpdate #GoldInvesting

Proactive - Interviews for investors

Nostra Terra Oil and Gas CEO on Fouke field growth plans, 5,000 barrels a day target

Nostra Terra Oil and Gas Company PLC CEO Paul Welch talked with Proactive's Stephen Gunnion about the company’s strategy to scale up production and drive growth from its existing base of operations in East Texas and West Texas. Welch explained that Nostra Terra is currently focused on the Pine Mills field, a long-life, shallow onshore field with low operating costs and consistent profitability. “It's been an exciting field for the last 75 years and we expect it to be an exciting field for the program for the next 20 to 30 as well,” he said. Since taking over as CEO around nine months ago, Welch has led the company to profitability by cutting costs and increasing production. He highlighted two successful well workover programs that have effectively doubled production. A key highlight is the Fouke area, where new drilling, including the upcoming Fouke-3 well, could deliver significant volumes. Welch pointed out that these wells can initially produce around 120 barrels per day—compared to the average of 6 to 10 barrels from the Pine Mills wells. If enhanced recovery schemes are implemented, the output could potentially double. Welch reaffirmed the company’s ambitious growth target: “This is a company that's going to be making 5,000 barrels a day in the next 3 to 5 years.” The focus remains on building from a solid, profitable base, with production costs in the Fouke area as low as $3 to $4 per barrel, ensuring resilience across various oil price environments. Watch the full interview to hear more on the outlook for 2025, drilling plans, and the strategic path forward. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and enable notifications to stay updated on the latest content. #NostraTerra #OilAndGas #PaulWelch #TexasOil #PineMillsField #FoukeArea #EnergyStocks #OilProduction #InvestorUpdate #ProactiveInvestors

Proactive - Interviews for investors

Genflow Biosciences adds AI power to gene therapy through Heureka Labs collaboration

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new strategic partnership with US-based Heureka Labs, a spinoff of Duke University, to enhance its gene therapy research using AI technology. Leire said: “Every biotech in gene therapy should have an AI component. If you don't have that, you miss a critical tool to unlock value for your shareholders.” He stressed the need for a multi-omics approach—genomic, transcriptomic, and proteomic—to better understand gene expression and drug response, which traditional analysis methods struggle to fully capture. The partnership with Heureka Labs, which integrates deep AI and biological expertise, will initially support Genflow’s lead candidate, GF-1002, a SIRT-6 gene therapy targeting MASH (metabolic dysfunction-associated steatohepatitis). AI will help the company analyse complex preclinical data, including insights from nearly 700 mice tested, to understand mechanisms of action and identify likely responders—crucial in discussions with regulators such as the FDA and EMA. Leire also emphasised that the collaboration is scalable across Genflow’s pipeline, helping unlock synergies between programmes in liver, muscle, and eye diseases. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #GeneTherapy #AIinBiotech #BiotechNews #MASH #SIRT6 #HeurekaLabs #DrugDevelopment #MultiOmics #BiotechPartnership #FDA #EMA #PreclinicalResearch

Followers	77
Posts	19332
Boards Moderated	2
Alias Born	04/16/2019

Volume:	8,930,688
Day Range:	0.00085 - 0.0011
Bid:	0.0008
Ask:	0.0009
Last Trade Time:	3:47:29 PM EDT
Total Trades:	29

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

MVCO Detailed Quote

Recent MVCO News

More MVCO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent MVCO News

Go Ad-Free